A compound heterozygote harboring novel and recurrent DTDST mutations with intermediate phenotype between atelosteogenesis type II and diastrophic dysplasia
✍ Scribed by Koichi Maeda; Yoshinari Miyamoto; Hideaki Sawai; Lawrence P. Karniski; Eiji Nakashima; Gen Nishimura; Shiro Ikegawa
- Publisher
- John Wiley and Sons
- Year
- 2006
- Tongue
- English
- Weight
- 183 KB
- Volume
- 140A
- Category
- Article
- ISSN
- 1552-4825
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
Diastrophic dysplasia sulfate transporter (DTDST) is a sulfate transporter required for the synthesis of sulfated proteoglycans in the cartilage. Over 30 mutations have been described in the DTDST gene, which result in a continuous clinical spectrum of recessively inherited chondrodysplasias, including, in order of increasing severity, a recessive form of multiple epiphyseal dysplasia (rMED), diastrophic dysplasia (DTD), atelosteogenesis type II (AO‐II) and achondrogenesis 1B (ACG‐1B). Correlation between disease severity and residual sulfate transport activity has been reported. Here we report a patient with DTDST mutations, whose manifestations fell in a range between AO‐II and DTD. The patient was a compound heterozygote for the recurrent c.835C>T (p.R279W) and novel c.1987G>A (p.G663R) mutations. Immunocytochemical analysis in HEK293 cells showed that the p.G663R mutation was localized within the cytoplasm, and not to the cell membrane, suggesting p.G663R is a loss‐of‐function mutation. Our case supports the previously described correlation between the severity of the phenotype and the putative level of residual transport function. © 2006 Wiley‐Liss, Inc.